Nurix director granted 31,250 stock options

Nurix Therapeutics director Roy D. Baynes received a grant of 31,250 stock options to buy Nurix common stock.

Rhea-AI Filing Summary

Nurix Therapeutics director Roy D. Baynes received a grant of 31,250 stock options to buy Nurix common stock. The options have an exercise price of $15.86 per share and expire on May 14, 2036, providing long-term equity-based compensation.

The award vests 100% on the earlier of the company’s next annual stockholder meeting or May 15, 2027, so long as Baynes continues to provide service through the vesting date. After this grant, he holds 31,250 derivative securities linked to Nurix common stock directly.

Insider Trade Summary

Grant/Award: 31,250 shares

Grant/Award 1 txn

Insider Baynes Roy D.

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Director Stock Option (right to buy)	31,250	$0.00	$0.00

Holdings After Transaction: Director Stock Option (right to buy) — 31,250 contracts (Direct)

Footnotes (1)

1. F1. The stock option vests as to 100% of the award on the earlier of (a) the date of the next annual meeting of the Issuer's stockholders and (b) May 15, 2027, in each case, subject to the Reporting Person's provision of service to the Issuer on such vesting date.

Key Figures

Options granted: 31,250 options Exercise price: $15.86 per share Expiration date: May 14, 2036 +2 more

5 metrics

Options granted 31,250 options Director stock option award to Roy D. Baynes

Exercise price $15.86 per share Exercise price of director stock options

Expiration date May 14, 2036 Option term end for the grant

Vesting deadline May 15, 2027 Latest possible full vesting date, subject to service

Total derivatives after grant 31,250 options Total derivative securities held directly after transaction

Key Terms

Director Stock Option (right to buy), exercise price, expiration date, vests as to 100% of the award

4 terms

Director Stock Option (right to buy) financial

"security_title: Director Stock Option (right to buy)"

exercise price financial

"conversion_or_exercise_price: 15.8600"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

expiration date financial

"expiration_date: 2036-05-14T00:00:00.000Z"

The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.

vests as to 100% of the award financial

"The stock option vests as to 100% of the award on the earlier"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Nurix Therapeutics (NRIX) report for Roy D. Baynes?

Nurix reported that director Roy D. Baynes received a grant of 31,250 stock options. These options are compensation-based awards, not an open-market share purchase, and give him the right to buy Nurix common stock at a fixed exercise price in the future.

How many stock options did Roy D. Baynes receive in this NRIX Form 4 filing?

Roy D. Baynes received 31,250 Director Stock Options in this transaction. Each option is a right to buy one share of Nurix common stock, aligning his compensation with shareholder interests through potential future stock price appreciation.

What is the exercise price and expiration date of the Nurix stock options granted to Baynes?

The options have an exercise price of $15.86 per share and expire on May 14, 2036. This means Baynes can choose to buy Nurix common stock at $15.86 any time before that expiration date, once the options are vested.

When do Roy D. Baynes’s Nurix director stock options vest?

The options vest 100% on the earlier of Nurix’s next annual stockholder meeting or May 15, 2027. Vesting is conditional on Baynes continuing to provide service to Nurix through the applicable vesting date specified in the award terms.

Is the Baynes Form 4 transaction a market purchase of NRIX shares?

No, the transaction is a grant of stock options as compensation, not a market share purchase. Baynes acquires the right to buy shares later at $15.86, but no open-market buying or selling occurred in this reported transaction.

How many Nurix-related derivative securities does Roy D. Baynes hold after this grant?

Following this grant, Baynes holds 31,250 derivative securities tied to Nurix common stock directly. This entire amount comes from the newly awarded director stock options reported in the filing, reflecting his current option position from this grant.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 05/15/2026 - 05:42 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Baynes Roy D.

(Last) (First) (Middle)

C/O NURIX THERAPEUTICS, INC.

1600 SIERRA POINT PKWY

(Street)

BRISBANE CALIFORNIA 94005

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Nurix Therapeutics, Inc. [ NRIX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/15/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Director Stock Option (right to buy)	$15.86	05/15/2026		A		31,250		(1)	05/14/2036	Common Stock	31,250	$0	31,250	D

Explanation of Responses:

1. The stock option vests as to 100% of the award on the earlier of (a) the date of the next annual meeting of the Issuer's stockholders and (b) May 15, 2027, in each case, subject to the Reporting Person's provision of service to the Issuer on such vesting date.

Remarks:

	/s/ Daniel Burbach, as Attorney-in-Fact for Roy D. Baynes	05/15/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)